A CFO's guide to denial prevention, AR days, and payer contract strategy

The number that should stop every CFO cold: 57% of appealed Medicare Advantage denials are ultimately overturned. Most denials hospitals fight were never clinically justified.

Yet hospitals spent nearly $18 billion overturning denials in 2025, and true AR days rose 5.2% year-over-year anyway. The effort is real. The results are getting worse.

Why Working Harder Isn't Working

The delay is upstream, in payer queues, not your billing department. Rising request-for-information denials and slower payer response times are the documented drivers of the 5.2% AR-day increase. Your team can process appeals faster without moving that number.

The scale is no longer a back-office line item. The AHA estimates $43 billion spent trying to collect payments insurers owe for care already delivered. Medicare Advantage sharpens it: MA denial rates spiked 4.8% from 2023 to 2024, a Health Affairs study covering 30% of the market found 17% initial denial rates, and the average denied MA claim rose 22.4% year-over-year to roughly $1,000.

As an Adonis survey of RCM leaders reported this year: “In 2026, revenue performance is increasingly dictated by payer behavior rather than patient volume or internal capacity.”

The shift has reached leadership. In a survey of 882 provider-side executives, 78% ranked payer friction among their top three RCM stressors, 74% now prioritize denial prevention over post-denial recovery, and 66% said their current analytics are insufficient for CFO-grade decisions. As Black Book's Doug Brown put it, RCM has reached its “boardroom moment.”

The Playbook: Five Moves This Quarter

1. Segment AR aging by payer and denial type

Why Blended AR-day metrics hide the drag. Low-friction commercial claims average out against MA disputes that sit in limbo for months, so the total tells you nothing about where cash is actually stuck.

Do this Break your AR aging report into buckets by payer tier and denial reason. Start with your top five payers by volume.

Track Days-in-AR per payer, and % of AR older than 90 days per payer.

2. Move the denial team upstream

Why Fighting a denial costs money and time you have already spent. Prevention is cheaper than recovery, which is why 74% of executives now prioritize it.

Do this Shift staff toward pre-authorization workflows, payer-specific documentation checks, and front-end eligibility verification, so fewer claims ever reach the appeal queue.

Track Clean-claim rate on first submission, and denial volume entering the appeal queue month-over-month.

3. Audit your MA contract portfolio before renewal

Why Providers are already walking. Brown University Health, Moffitt, and NewYork-Presbyterian have all cut MA contracts in 2026: Moffitt dropped Aetna MA and exits Humana MA in July, and NewYork-Presbyterian went out of network with UnitedHealthcare MA on June 30. With MA covering more than half of older adults, these decisions carry real access weight, so bring facts.

Do this Run a plan-level profitability analysis: net revenue after denial-related administrative cost, per contract. Rank your MA plans worst to best.

Track Net-revenue-after-denial-cost per plan, ahead of each renewal date.

4. Comment on the CY 2027 OPPS/ASC rule by August 31

Why CMS released the proposed rule on July 2, 2026. The 2.4% headline update is offset for many by cuts to certain outpatient drug reimbursement, expanded site-neutral policies, and faster recovery of prior budget-neutrality adjustments. For HOPDs and ASCs the net could be materially worse than the headline.

Do this Submit comments on the record before the August 31 deadline. This also creates a documented basis for your own compliance and renegotiation planning.

Track Comment submitted (yes/no), and modeled reimbursement impact of the site-neutral and 340B provisions on your outpatient lines.

5. Demand CFO-grade analytics from your RCM stack

Why Two-thirds of executives say their analytics can't support CFO-level decisions. You cannot defend a cash-flow projection built on data you already know is inadequate.

Do this Require your reporting to show four things at minimum: payer-specific denial rates, appeal success rates, time-to-payment by payer, and denial cost per claim. If it can't, that is your next procurement conversation.

Track Whether all four metrics are visible in one view, refreshed at least monthly.

On the Watchlist

H.R. 3514, the Improving Seniors' Timely Access to Care Act, cleared the House Energy and Commerce Subcommittee on Health by voice vote in late June with 290-plus bipartisan cosponsors. It would force MA plans to report prior-authorization approval and denial data to HHS, including for surgeries and invasive procedures. It won't cut denial rates directly, but it makes payer patterns visible and harder to defend. Watch for floor movement.

Bottom Line

The $18 billion hospitals spent fighting denials in 2025 did not stop AR days from rising. Unjustified denials are growing faster than the capacity to appeal them, and each fight costs more as denied amounts climb. The organizations protecting margin aren't appealing harder. They are restructuring the front end to keep denials out of the queue and using contract leverage to hold payers accountable.